Decipher Genomics Resource for Intelligent Discovery (GRID®)

GenomeDx Biosciences

Status: Invitation-only

Conditions: Bladder Cancer; Renal Cancer; Prostate Cancer

Treatments: Other: Decipher Cancer Classifier

Study type: Observational

Funder types: Industry

Identifiers

NCT02609269

GRD001

Details and patient eligibility

About

To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.

Full description

Observational study involving the release of tumor genome-wide expression and whole slide imaging data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics and histopathologic features of cancer and discover or validate gene expression signatures as well as digital pathology models that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.

Enrollment: 1,000,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Subjects that have had a Decipher clinical test

Trial design

1,000,000 participants in 1 patient group

Decipher GRID Patients

Description:

Patients who have been tested with any of the Decipher clinical tests

Treatment:

Other: Decipher Cancer Classifier